Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jul;36(7):1187-1196.
doi: 10.1007/s10096-017-2907-x. Epub 2017 Jan 21.

Antimicrobial combination treatment including ciprofloxacin decreased the mortality rate of Pseudomonas aeruginosa bacteraemia: a retrospective cohort study

Affiliations

Antimicrobial combination treatment including ciprofloxacin decreased the mortality rate of Pseudomonas aeruginosa bacteraemia: a retrospective cohort study

M Paulsson et al. Eur J Clin Microbiol Infect Dis. 2017 Jul.

Abstract

Ineffective antimicrobial therapy of Pseudomonas aeruginosa bacteraemia increases mortality. Recent studies have proposed the use of antimicrobial combination therapy composed of a beta-lactam with either ciprofloxacin or tobramycin. To determine if combination therapy correlates to lower mortality and is superior compared to monotherapy, we investigated the effect of antimicrobial treatment regimens on 30-day mortality in a cohort with Pseudomonas aeruginosa bacteraemia. All cases of P. aeruginosa bacteraemia (n = 292) in southwest Skåne County, Sweden (years 2005-2010, adult population 361,112) and the whole county (2011-2012, 966,130) were identified. Available medical and microbiological records for persons aged 18 years or more were reviewed (n = 235). Antimicrobial therapy was defined as empiric at admission or definitive after culture results and was correlated to 30-day mortality in a multivariate regression model. The incidence and mortality rates were 8.0 per 100,000 adults and 22.9% (67/292), respectively. As expected, multiple comorbidities and high age were associated with mortality. Adequate empiric or definitive antipseudomonal treatment was associated with lower mortality than other antimicrobial alternatives (empiric p = 0.02, adj. p = 0.03; definitive p < 0.001, adj. p = 0.007). No difference in mortality was seen between empiric antipseudomonal monotherapy or empiric combination therapy. However, definitive combination therapy including ciprofloxacin correlated to lower mortality than monotherapy (p = 0.006, adj. p = 0.003), whereas combinations including tobramycin did not. Our results underline the importance of adequate antipseudomonal treatment. These data also suggest that P. aeruginosa bacteraemia should be treated with an antimicrobial combination including ciprofloxacin when susceptible.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest

Dr Jonas Ahl has received speaker honorarium from Pfizer, AstraZeneca, Meda and MSD, and research grants from Pfizer for a study not related to the present work. All remaining authors declare that they have no conflicts of interest.

Ethical approval

Informed consent was not relevant to this retrospective study according to the Regional Ethical Review Board in Lund, Sweden, who granted approval of the present study (Dnr 2014/10).

Figures

Fig. 1
Fig. 1
Patients included in this study. Flow chart summarising the number of cases in the present study and the reason for exclusion for some analyses
Fig. 2
Fig. 2
Pseudomonas aeruginosa bacteraemia incidence increases with age. Incident cases of P. aeruginosa bacteraemia were older (a, bars, left y-axis) than the population in Skåne County (a, curve, right y-axis). In all age groups, the incidence of P. aeruginosa bacteraemia was higher among males than females and increased with higher age (b). No increase in incidence was seen over the entire study period (c, left y-axis), even though the number of analysed blood cultures increased (c, right y-axis)
Fig. 3
Fig. 3
Ciprofloxacin-treated cases had a lower 30-day mortality. Thirty-day mortality rates in percent after treatment with ciprofloxacin or other antimicrobial drug as definitive therapy when culture results were available. The results were stratified by age groups (a), comorbidity as defined by the Charlson comorbidity index (CCI) (b) or infection focus (c)

References

    1. Kelsey M. Pseudomonas in augmented care: should we worry? J Antimicrob Chemother. 2013;68:2697–2700. doi: 10.1093/jac/dkt288. - DOI - PubMed
    1. Finland M, Jones WF, Jr, Barnes MW. Occurrence of serious bacterial infections since introduction of antibacterial agents. J Am Med Assoc. 1959;170:2188–2197. doi: 10.1001/jama.1959.63010180008012. - DOI - PubMed
    1. Osih RB, McGregor JC, Rich SE, Moore AC, Furuno JP, Perencevich EN, et al. Impact of empiric antibiotic therapy on outcomes in patients with Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother. 2007;51:839–844. doi: 10.1128/AAC.00901-06. - DOI - PMC - PubMed
    1. Al-Hasan MN, Wilson JW, Lahr BD, Eckel-Passow JE, Baddour LM. Incidence of Pseudomonas aeruginosa bacteremia: a population-based study. Am J Med. 2008;121:702–708. doi: 10.1016/j.amjmed.2008.03.029. - DOI - PMC - PubMed
    1. Parkins MD, Gregson DB, Pitout JDD, Ross T, Laupland KB. Population-based study of the epidemiology and the risk factors for Pseudomonas aeruginosa bloodstream infection. Infection. 2010;38:25–32. doi: 10.1007/s15010-009-9145-9. - DOI - PubMed

MeSH terms